Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...
HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human ...
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to ...
The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant prostate cancer.
today announced the first patient has been dosed in its first-in-human study evaluating ARC101, a potential best-in-class T cell engager targeting Claudin 6 (CLDN6). This Phase 1 study will ...
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback